Celldex Therapeutics reported $60.52M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Agenus USD 231.82M 17.42M Jun/2026
Amgen USD 23.23B 2.27B Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Celldex Therapeutics USD 60.52M 808K Sep/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Northwest Biotherapeutics USD 82.97M 4.93M Mar/2026
Pfizer USD 31.73B 920M Sep/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28.85B 846M Jun/2026